Respitide 25/250 solution

Dexa Medica

Ingredients in every dose

Salmeterol 25 mcg
Fluticasone 50 mcg

Each package contains

1 canister of 120 doses

Other details

Dosage form:Pressurised inhalation; solution
Flavour None

W.H.O. classification

ATC Level 1 R - Respiratory system
ATC Level 2 R03 - Drugs for Obstructive Airway Diseases
ATC Level 3 R03A - Adrenergics; Inhalants

Warnings

Pregnancy

CAUTIONThis item may not be safe for use during pregnancy. Use with caution and after consultation with your doctor.

Lactation

CAUTIONThis item may not be safe for use during lactation. Use with caution and after consultation with your doctor.

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

CONSULT YOUR DOCTORSafety of this item for use while operating heavy machinery has not been established. Please consult your doctor.

Available in

Indonesia

Dosage information

4 TO 12 YEARS OLD
Reversible obstructive airways disease (ROAD)
Two inhalations of 25 µg salmeterol and 50 µg fluticasone propionate twice daily

Respitide inhaler is for inhalation only.
Patients should be made aware that Respitide Inhaler must be used regularly for optimum benefit, even when asymptomatic.
Patients should be regularly reassessed by a doctor, so that the strength of Respitide they are receiving remains optimal and is only changed on medical advice.

12 TO 18 YEARS OLD
Reversible obstructive airways disease (ROAD)
Two inhalations of 25 µg salmeterol and 50 µg fluticasone propionate twice daily or two inhalations of 25 µg salmeterol and 125 µg fluticasone propionate twice daily or two inhalations of 25 µg salmeterol and 250 µg fluticasone propionate twice daily

Respitide inhaler is for inhalation only.
Patients should be made aware that Respitide Inhaler must be used regularly for optimum benefit, even when asymptomatic.
Patients should be regularly reassessed by a doctor, so that the strength of Respitide they are receiving remains optimal and is only changed on medical advice.

18 YEARS OLD AND ABOVE
Reversible obstructive airways disease (ROAD)
Doubling the dose of all strengths of RESPITIDE in adults for up to 14 days has comparable safety and tolerability to regular twice daily dosing and may be considered when patients require additional short-term (up to 14 days) inhaled corticosteroid therapy as outlined in asthma treatment guidelines.

Chronic obstructive pulmonary disease (COPD)
For adults patients the recommended dose is two inhalations 25/125 µg to 25/250 µg salmeterol/fluticasone propionate twice daily.

Respitide inhaler is for inhalation only.
Patients should be made aware that Respitide Inhaler must be used regularly for optimum benefit, even when asymptomatic.
Patients should be regularly reassessed by a doctor, so that the strength of Respitide they are receiving remains optimal and is only changed on medical advice.

0 TO 4 YEARS OLD
There are no data available for use of salmeterol/fluticasone propionate in children aged under 4 years.

Respitide inhaler is for inhalation only.
Patients should be made aware that Respitide Inhaler must be used regularly for optimum benefit, even when asymptomatic.
Patients should be regularly reassessed by a doctor, so that the strength of Respitide they are receiving remains optimal and is only changed on medical advice.

PATIENTS WITH HEPATIC IMPAIRMENT
There is no need to adjust the dose.

PATIENTS WITH RENAL IMPAIRMENT
There is no need to adjust the dose.

ELDERLY PATIENTS
There is no need to adjust the dose.

Indication

Reversible obstructive airways disease (ROAD)
Respitide is indicated in the regular treatment of reversible obstructive airways disease (ROAD), including asthma in children and Adults, where use of a combination (bronchodilator and inhaled corticosteroid) is appropriate. This may include:
– Patients on effective maintenance doses of long-acting ß-agonist and inhaled corticosteroids.
– Patients who are symptomatic on current inhaled corticosteroid therapy.
– Patients on regular bronchodilator therapy who require inhaled corticosteroids.

Chronic obstructive pulmonary disease (COPD)
Respitide is indicated for the regular treatment of chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema.